Research programme: signal transduction pathway inhibitors - Athersys/Cleveland Clinic Foundation
Latest Information Update: 26 Feb 2009
At a glance
- Originator Athersys; The Cleveland Clinic Foundation
- Class
- Mechanism of Action Signal transduction pathway inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cancer; Inflammation
Most Recent Events
- 15 Jun 2004 Preclinical trials in Asthma in USA (unspecified route)
- 11 Dec 2002 This programme is still in active development
- 12 Mar 2001 Preclinical development for Cancer in USA (Unknown route)